GammaCan Retains Investor Relations Firm ROI Group

  
    
  
  
    
      GammaCan International, Inc. (“GammaCan” 
      or “the Company”) 
      (OTCBB: GCAN), a developer of proprietary immunotherapies for the 
      treatment of melanoma and other cancers, today announced it has retained 
      investor relations firm ROI Group.
    
    
      GammaCan develops proprietary immunotherapy and related approaches to 
      treat melanoma and other cancers. GammaCan's platform patented 
      technology is based on the use of IgGs (gamma-immunoglobulins), a safe, 
      relatively non-toxic human plasma-derived product used to treat a 
      variety of immune deficiencies and autoimmune diseases. In cancer, 
      IgG-based therapies work by strengthening the patient's immune system. 
      Many experts currently view immunotherapy as a future alternative to 
      chemotherapy. The Company’s lead drug 
      candidate, VitiGam™, targets Stage lll and 
      Stage lV melanoma for which no effective treatment currently exists.
    
    
      In making the announcement, Steven Katz, Chairman of the Board and 
      President of GammaCan said, “In seeking to 
      establish GammaCan as a leader in developing novel immunotherapy and 
      related approaches to cancer, we are rapidly moving forward with 
      multiple strategic initiatives. VitiGam™, 
      targeting Stage III and Stage IV melanoma, is slated to enter Phase I/II 
      human clinical trials in early 2008.”
    
    
      “As we approach submitting an IND and 
      initiating clinical trials, it is now an appropriate time to broaden our 
      shareholder base by presenting GammaCan to retail and institutional 
      investors,” Mr. Katz continued.
    
    
      Robert Giordano, a Managing Partner of ROI Group, commented on ROI’s 
      appointment, “We are very excited to work 
      with GammaCan in communicating their leading-edge IgG-based 
      immunotherapy approach to treating various cancers, particularly 
      advanced stage melanoma.”
    
    
      “ROI has a track record for delivering 
      successful investor relations strategies tailored to the requirements of 
      small cap life science companies to maximize shareholder value. We 
      anticipate the same with GammaCan,” said Mr. 
      Giordano.
    
    
      About VitiGam™
    
    
      VitiGam™ is a first-in-class IgG-based 
      anti-cancer immunotherapy being developed for the treatment of Stage III 
      and Stage IV melanoma. GammaCan is planning to submit its 
      Investigational New Drug Application (IND) for VitiGam™ 
      to the FDA in the near future. The Company expects to commence human 
      clinical trials shortly thereafter. VitiGam™ 
      is an IgG-based product manufactured from the plasma of donors with 
      Vitiligo, a benign skin condition affecting up to 2% of the general 
      population. Studies have shown that this "enriched" IgG formulation 
      contains potent anti-melanoma activity. Based on these studies, GammaCan 
      expects VitiGam™ to provide both, specific 
      anti-melanoma activity (directed against melanoma cells), and 
      non-specific anti-cancer activity.
    
    
      About Melanoma
    
    
      Melanoma is a deadly form of skin cancer. According to the American 
      Cancer Society, melanoma accounts for approximately 4% of all skin 
      cancers but causes approximately 75% of all skin cancer-related deaths. 
      An estimated 62,000 people will be diagnosed with and nearly 8,000 
      people will die from melanoma in the U.S. alone in 2007. If rapidly 
      diagnosed and surgically removed, early-stage melanoma is usually 
      curable. However, for patients with metastatic melanoma (Stage III and 
      Stage IV), the prognosis is poor since no effective treatment currently 
      exists. These patients have a median survival time of 8.5 months and a 
      5-year survival rate of less than 10%. There has been little change in 
      these results for in excess of 25 years. The incidence of melanoma has 
      increased more rapidly than any other cancer during the past 10 years. 
      The last drug to treat patients with metastatic melanoma was approved by 
      the FDA over 30 years ago.
    
    
      For more information about GammaCan, visit www.GammaCan.com.
    
    
      Safe Harbor Statement
    
    
      Statements in this document that are not purely historical are 
      forward-looking statements. Forward-looking statements in this release 
      include statements regarding: the commercialization of anti-cancer 
      immunotherapies and the Company's efforts to develop therapies to boost 
      the immune systems of cancer patients by the use of IgG-based therapy. 
      Actual outcomes and the Company's actual results could differ materially 
      from those in such forward-looking statements. Factors that could cause 
      actual results to differ materially include risks and uncertainties such 
      as the inability to finance the planned development of the technology, 
      the inability to hire appropriate staff to develop the technology, 
      unforeseen technical difficulties in developing the technology, the 
      inability to obtain regulatory approval for human use, competitors' 
      therapies proving to be more effective, cheaper or otherwise preferable 
      for consumers, the inability to market a product, all of which could, 
      among other things, delay or prevent product release, as well as other 
      factors expressed from time to time in GammaCan's periodic filings with 
      the Securities and Exchange Commission (the "SEC"). As a result, this 
      press release should be read in conjunction with GammaCan's periodic 
      filings with the SEC, which are incorporated herein by reference. The 
      forward-looking statements contained herein are made only as of the date 
      of this press release and GammaCan undertakes no obligation to publicly 
      update such forward-looking statements to reflect subsequent events or 
      circumstances.